nvestorideas.com - NASDAQ Biotech/Pharma News: BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Positive LibiGel® Data Monitoring Committee Recommendation
Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications
Visit this company: www.biosantepharma.com
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
"We are very pleased that the DMC recommended that the study should continue without modification. This means that there are no general or specific safety issues based on their unblinded review of adverse events. The low number of CV events to date is consistent with the safety of testosterone in women," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante. "Once the DMC determines that there are enough subjects enrolled for statistical significance, enrollment of new subjects into the study will be complete. The current LibiGel safety study protocol allows for up to 4,000 women to be enrolled."
Another unblinded statistical analysis will be conducted by the DMC each time there is an additional adjudicated cardiovascular event. With approximately 2,300 women-years of exposure in the study, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, compared to an expected rate of CV events for this study of approximately two percent. Moreover, there have been seven breast cancers reported, a rate of approximately 0.32 percent, compared to an expected rate of approximately 0.35 percent.
Subjects have been in the study for an average of approximately 10.7 months. There are approximately 850 subjects who have been in the study for over one year and approximately 400 subjects who have been in the study for more than two years. The LibiGel Phase III safety study represents the largest data base of the safety of testosterone in women. A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante's objective is to submit the LibiGel NDA in 2011.
The statistical analyses of the CV events are based on predefined statistical methods, in accordance with BioSante's agreement with the FDA, to determine if LibiGel can be considered safe for post-menopausal women. Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women.
"With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD," said Stephen M. Simes, BioSante's president & CEO.
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Monday, October 25, 2010
Investorideas.com - Biotech Stocks On the Move; (OTCBB: UVFT), (NASDAQ:CLRT), (OTCBB: ISCO), (NASDAQ: VRNM)
Investorideas.com - Biotech Stocks On the Move; (OTCBB: UVFT), (NASDAQ:CLRT), (OTCBB: ISCO), (NASDAQ: VRNM)
OTCBB: UVFT Trading $0.34-0.389, Clarient, Inc. (NasdaqCM: CLRT) Traded over 2 Million Shares
Share this news:
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
Point Roberts, WA - October 25, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, reports on Biotech/ Pharma Stocks recent news and trading.
At the time of this release, OTCBB: UVFT has a trading range of $0.34-0.389 and Clarient, Inc. (NasdaqCM: CLRT) has traded over 2 million shares.
Biotech Stocks to follow today based on Friday's volume and gains as well as last week's include UV Flu Technologies, Inc., (OTCBB: UVFT), Clarient, Inc. (NASDAQ: CLRT), International Stem Cell Corp. (OTCBB: ISCO) and Verenium (NGM:VRNM).
Sector Snapshot: (Trading at time of release for October 25)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $0.36, up 0.01 (2.86%)
Clarient, Inc. (NASDAQ:CLRT), trading at $ 4.9750,
International Stem Cell Corp. (OTCBB: ISCO) trading at $1.80, up 0.0690 (3.99%)
Verenium Corporation (Nasdaq: VRNM) trading at $3.85 USD
Biotech Stocks on the Move
UV Flu Technologies, Inc., (OTCBB: UVFT) Stock up 9.37% on the day
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
View latest research report at www.biotechstockpick.com
Latest News:
Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
"UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales ("NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Adds-iw-2297079947.html?x=0&.v=1
Website: http://www.uvflutech.com/ and www.biotechstockpick.com
Recent Research
Research Report Excerpt; Key Highlights on UVFT.OB -
Written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
10 reasons to invest in UVFT
...for what could be the killer biotech buy of the year with 370% profit potential!
FDA approval has already been received, allowing UVFT to market its product as a medical device-such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
Top 5 U.S. Hospitals Put UVFT Technology to Work-UVFT's UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
Independent laboratory testing proves UVFT's technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
This year's bad flu season is all it will take to send UVFT's share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available-and it won't be blue masks.
Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
Shares at the ground floor entry point of just $0.30- this is the stage you stand to make the biggest gains-this low price still has blue sky potential.
Experienced management team-a powerhouse team that's been with the heavyweights in health care and finance-those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
VFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Clarient, Inc. (NASDAQ:CLRT) Recent News: Stock up 33% on the day
"Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clrt) is investigating potential claims against the board of directors of Clarient, Inc. ("Clarient" or the "Company") (NASDAQ:CLRT - News) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million.”
Full Article: http://finance.yahoo.com/news/Ryan-Maniskas-LLP-Announces-bw-3775341173.html?x=0
Verenium Corporation (Nasdaq: VRNM) recent news - The shares rose $1.13 or 34.8 percent to $4.38 Wednesday on this news
Verenium Announces Regulatory Approval for Purifine® PLC in China
CAMBRIDGE, Mass., Oct. 20 Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that Purifine® PLC, the Company's novel enzyme specifically developed for the edible oil industry, has received all necessary Chinese government authorizations for sale as a processing aid in the edible oil industry. With this regulatory approval, Verenium now has the ability to sell Purifine® PLC in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China.
Full news – see company website http://www.verenium.com.
Research more biotech stocks at the Biotech stocks Directory:http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
OTCBB: UVFT Trading $0.34-0.389, Clarient, Inc. (NasdaqCM: CLRT) Traded over 2 Million Shares
Share this news:
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
Point Roberts, WA - October 25, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, reports on Biotech/ Pharma Stocks recent news and trading.
At the time of this release, OTCBB: UVFT has a trading range of $0.34-0.389 and Clarient, Inc. (NasdaqCM: CLRT) has traded over 2 million shares.
Biotech Stocks to follow today based on Friday's volume and gains as well as last week's include UV Flu Technologies, Inc., (OTCBB: UVFT), Clarient, Inc. (NASDAQ: CLRT), International Stem Cell Corp. (OTCBB: ISCO) and Verenium (NGM:VRNM).
Sector Snapshot: (Trading at time of release for October 25)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $0.36, up 0.01 (2.86%)
Clarient, Inc. (NASDAQ:CLRT), trading at $ 4.9750,
International Stem Cell Corp. (OTCBB: ISCO) trading at $1.80, up 0.0690 (3.99%)
Verenium Corporation (Nasdaq: VRNM) trading at $3.85 USD
Biotech Stocks on the Move
UV Flu Technologies, Inc., (OTCBB: UVFT) Stock up 9.37% on the day
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
View latest research report at www.biotechstockpick.com
Latest News:
Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
"UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales ("NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Adds-iw-2297079947.html?x=0&.v=1
Website: http://www.uvflutech.com/ and www.biotechstockpick.com
Recent Research
Research Report Excerpt; Key Highlights on UVFT.OB -
Written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
10 reasons to invest in UVFT
...for what could be the killer biotech buy of the year with 370% profit potential!
FDA approval has already been received, allowing UVFT to market its product as a medical device-such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
Top 5 U.S. Hospitals Put UVFT Technology to Work-UVFT's UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
Independent laboratory testing proves UVFT's technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
This year's bad flu season is all it will take to send UVFT's share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available-and it won't be blue masks.
Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
Shares at the ground floor entry point of just $0.30- this is the stage you stand to make the biggest gains-this low price still has blue sky potential.
Experienced management team-a powerhouse team that's been with the heavyweights in health care and finance-those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
VFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Clarient, Inc. (NASDAQ:CLRT) Recent News: Stock up 33% on the day
"Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clrt) is investigating potential claims against the board of directors of Clarient, Inc. ("Clarient" or the "Company") (NASDAQ:CLRT - News) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million.”
Full Article: http://finance.yahoo.com/news/Ryan-Maniskas-LLP-Announces-bw-3775341173.html?x=0
Verenium Corporation (Nasdaq: VRNM) recent news - The shares rose $1.13 or 34.8 percent to $4.38 Wednesday on this news
Verenium Announces Regulatory Approval for Purifine® PLC in China
CAMBRIDGE, Mass., Oct. 20 Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that Purifine® PLC, the Company's novel enzyme specifically developed for the edible oil industry, has received all necessary Chinese government authorizations for sale as a processing aid in the edible oil industry. With this regulatory approval, Verenium now has the ability to sell Purifine® PLC in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China.
Full news – see company website http://www.verenium.com.
Research more biotech stocks at the Biotech stocks Directory:http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Sport Distributor Deploys UV Flu Technologies (OTCBB: UVFT) Air Purifying Units For Well-Known Hockey Team's Locker Room
Investorideas.com - Sport Distributor Deploys UV Flu Technologies (OTCBB: UVFT) Air Purifying Units For Well-Known Hockey Team's Locker Room
"This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams," stated Charles Gulteri, President of NESSI (New England Sports Sales)
Visit this company: www.uvflutech.com
CENTERVILLE, MA - October 25, 2010 (InvestorIdeas.com Newswire, www.biotechindustrystocks.com) - UV Flu Technologies, Inc. (OTC.BB:UVFT) reports New England Sports Sales ("NESSI"), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order for ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
"This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams," stated Charles Gulteri, President of NESSI. "Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available.
The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400's ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world." said Mr. Gulteri.
"Athletic locker rooms are becoming a surprisingly robust area of interest for our product," said Jack Lennon, President of UV Flu Technologies. "Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks DirectoryBiotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
"This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams," stated Charles Gulteri, President of NESSI (New England Sports Sales)
Visit this company: www.uvflutech.com
CENTERVILLE, MA - October 25, 2010 (InvestorIdeas.com Newswire, www.biotechindustrystocks.com) - UV Flu Technologies, Inc. (OTC.BB:UVFT) reports New England Sports Sales ("NESSI"), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order for ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
"This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams," stated Charles Gulteri, President of NESSI. "Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available.
The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400's ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world." said Mr. Gulteri.
"Athletic locker rooms are becoming a surprisingly robust area of interest for our product," said Jack Lennon, President of UV Flu Technologies. "Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks DirectoryBiotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Sunday, October 24, 2010
Biotech Stocks to Watch for Monday; (OTCBB: UVFT),(NASDAQ:CLRT), (AMEX: PIP) , (NASDAQ: VRNM)
Biotech Stocks to Watch for Monday; (OTCBB: UVFT),(NASDAQ:CLRT), (AMEX: PIP) , (NASDAQ: VRNM)
Biotech Investors see wins for the week of 15-39% on top gainers
Point Roberts, WA –October 24, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, reports on Biotech/ Pharma Stocks recent news and trading.
Biotech Stocks to follow Monday based on Friday’s volume and gains as well as last week’s include UV Flu Technologies, Inc., (OTCBB: UVFT), Clarient, Inc. (NASDAQ: CLRT), PharmAthene, Inc. (AMEX:PIP) and Verenium (NGM:VRNM).
Last weeks biotech stock leaders included Clarient, NASDAQ: CLRT), Verenium (NGM:VRNM). (Pharmathene (AMEX:PIP), Aryx Therapeutics (ARYX) and Labopharm (DDS) . Biotech investors trading these stocks last week saw gains of 15- 39%.
Sector Snapshot: (Trading at Market close Friday October 22)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $0.35, up 0.03 (9.37%)
Clarient, Inc. (NASDAQ:CLRT), trading at $ 4.97, up 1.2350 (33.02%) on 50,532,499 volume of shares
PharmAthene, Inc. (AMEX:PIP) trading at $3.85, -0.04 (-1.03%)
Verenium Corporation (Nasdaq: VRNM) trading at $4.00 USD, up 0.18 (4.71%)
Biotech Stocks on the Move
UV Flu Technologies, Inc., (OTCBB: UVFT) Stock up 9.37% on the day
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
View latest research report at http://www.biotechstockpick.com/
Latest News:
Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
“UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Adds-iw-2297079947.html?x=0&.v=1
Website: http://www.uvflutech.com/ and www.biotechstockpick.com
Recent Research
Research Report Excerpt; Key Highlights on UVFT.OB –
Written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
10 reasons to invest in UVFT
…for what could be the killer biotech buy of the year with 370% profit potential!
1. FDA approval has already been received, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
2. Top 5 U.S. Hospitals Put UVFT Technology to Work—UVFT’s UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
3. Independent laboratory testing proves UVFT’s technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
4. OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
5. This year’s bad flu season is all it will take to send UVFT’s share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won’t be blue masks.
6. Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
7. Shares at the ground floor entry point of just $0.30— this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
8. Experienced management team—a powerhouse team that’s been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
9. THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
10. UVFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Clarient, Inc. (NASDAQ:CLRT) Recent News: Stock up 33% on the day
“Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clrt) is investigating potential claims against the board of directors of Clarient, Inc. ("Clarient" or the "Company") (NASDAQ:CLRT - News) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million.”
Full Article: http://finance.yahoo.com/news/Ryan-Maniskas-LLP-Announces-bw-3775341173.html?x=0
Verenium Corporation (Nasdaq: VRNM) recent news –
The shares rose $1.13 or 34.8 percent to $4.38 Wednesday on this news
Verenium Announces Regulatory Approval for Purifine® PLC in China
CAMBRIDGE, Mass., Oct. 20 Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that Purifine® PLC, the Company's novel enzyme specifically developed for the edible oil industry, has received all necessary Chinese government authorizations for sale as a processing aid in the edible oil industry. With this regulatory approval, Verenium now has the ability to sell Purifine® PLC in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China.
Full news – see company website http://www.verenium.com/.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Biotech Investors see wins for the week of 15-39% on top gainers
Point Roberts, WA –October 24, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, reports on Biotech/ Pharma Stocks recent news and trading.
Biotech Stocks to follow Monday based on Friday’s volume and gains as well as last week’s include UV Flu Technologies, Inc., (OTCBB: UVFT), Clarient, Inc. (NASDAQ: CLRT), PharmAthene, Inc. (AMEX:PIP) and Verenium (NGM:VRNM).
Last weeks biotech stock leaders included Clarient, NASDAQ: CLRT), Verenium (NGM:VRNM). (Pharmathene (AMEX:PIP), Aryx Therapeutics (ARYX) and Labopharm (DDS) . Biotech investors trading these stocks last week saw gains of 15- 39%.
Sector Snapshot: (Trading at Market close Friday October 22)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $0.35, up 0.03 (9.37%)
Clarient, Inc. (NASDAQ:CLRT), trading at $ 4.97, up 1.2350 (33.02%) on 50,532,499 volume of shares
PharmAthene, Inc. (AMEX:PIP) trading at $3.85, -0.04 (-1.03%)
Verenium Corporation (Nasdaq: VRNM) trading at $4.00 USD, up 0.18 (4.71%)
Biotech Stocks on the Move
UV Flu Technologies, Inc., (OTCBB: UVFT) Stock up 9.37% on the day
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
View latest research report at http://www.biotechstockpick.com/
Latest News:
Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
“UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Adds-iw-2297079947.html?x=0&.v=1
Website: http://www.uvflutech.com/ and www.biotechstockpick.com
Recent Research
Research Report Excerpt; Key Highlights on UVFT.OB –
Written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
10 reasons to invest in UVFT
…for what could be the killer biotech buy of the year with 370% profit potential!
1. FDA approval has already been received, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
2. Top 5 U.S. Hospitals Put UVFT Technology to Work—UVFT’s UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
3. Independent laboratory testing proves UVFT’s technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
4. OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
5. This year’s bad flu season is all it will take to send UVFT’s share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won’t be blue masks.
6. Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
7. Shares at the ground floor entry point of just $0.30— this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
8. Experienced management team—a powerhouse team that’s been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
9. THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
10. UVFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Clarient, Inc. (NASDAQ:CLRT) Recent News: Stock up 33% on the day
“Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clrt) is investigating potential claims against the board of directors of Clarient, Inc. ("Clarient" or the "Company") (NASDAQ:CLRT - News) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million.”
Full Article: http://finance.yahoo.com/news/Ryan-Maniskas-LLP-Announces-bw-3775341173.html?x=0
Verenium Corporation (Nasdaq: VRNM) recent news –
The shares rose $1.13 or 34.8 percent to $4.38 Wednesday on this news
Verenium Announces Regulatory Approval for Purifine® PLC in China
CAMBRIDGE, Mass., Oct. 20 Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that Purifine® PLC, the Company's novel enzyme specifically developed for the edible oil industry, has received all necessary Chinese government authorizations for sale as a processing aid in the edible oil industry. With this regulatory approval, Verenium now has the ability to sell Purifine® PLC in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China.
Full news – see company website http://www.verenium.com/.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Friday, October 22, 2010
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
College and Professional Hockey Company adds UV Flu Technologies line of Indoor Air Quality Products to Locker rooms for Pro Hockey Team
CENTERVILLE, MA – October 22, 2010 -(InvestorIdeas.com Newswire, www.biotechindustrystocks.com – UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
“This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams,” stated Charles Gulteri, President of NESSI. “Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available. The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400’s ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world.” said Mr. Gulteri.
“Athletic locker rooms are becoming a surprisingly robust area of interest for our product,” said Jack Lennon, President of UV Flu Technologies. “Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months,” said Mr. Lennon.
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com
Sales: www.puravair.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
( please read disclosure and disclaimers )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
College and Professional Hockey Company adds UV Flu Technologies line of Indoor Air Quality Products to Locker rooms for Pro Hockey Team
CENTERVILLE, MA – October 22, 2010 -(InvestorIdeas.com Newswire, www.biotechindustrystocks.com – UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
“This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams,” stated Charles Gulteri, President of NESSI. “Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available. The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400’s ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world.” said Mr. Gulteri.
“Athletic locker rooms are becoming a surprisingly robust area of interest for our product,” said Jack Lennon, President of UV Flu Technologies. “Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months,” said Mr. Lennon.
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com
Sales: www.puravair.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
( please read disclosure and disclaimers )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Adds Boston Bruins as Latest High Profile ViraTech UV-400 Customer
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Adds Boston Bruins as Latest High Profile ViraTech UV-400 Customer
CENTERVILLE, MA – October 22, 2010 -(InvestorIdeas.com Newswire, www.biotechindustrystocks.com – UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
“This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams,” stated Charles Gulteri, President of NESSI. “Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available. The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400’s ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world.” said Mr. Gulteri.
“Athletic locker rooms are becoming a surprisingly robust area of interest for our product,” said Jack Lennon, President of UV Flu Technologies. “Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months,” said Mr. Lennon.
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com
Sales: www.puravair.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
( please read disclosure and disclaimers )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
CENTERVILLE, MA – October 22, 2010 -(InvestorIdeas.com Newswire, www.biotechindustrystocks.com – UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
“This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams,” stated Charles Gulteri, President of NESSI. “Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available. The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400’s ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world.” said Mr. Gulteri.
“Athletic locker rooms are becoming a surprisingly robust area of interest for our product,” said Jack Lennon, President of UV Flu Technologies. “Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months,” said Mr. Lennon.
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com
Sales: www.puravair.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
( please read disclosure and disclaimers )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Thursday, October 21, 2010
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Announces TV Segment Featuring Indoor Air Quality Biotech Products Completed and Ready for November Broadcast
Investorideas.com - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Announces TV Segment Featuring Indoor Air Quality Biotech Products Completed and Ready for November Broadcast
"Designing Spaces" TV Broadcast Features Solution for Indoor Air Quality during Holiday Flu and Cold Season
CENTERVILLE, MA - October 21, 2010 (Investorideas.com newswire, www.biotechindusgtrystocks.com ) Biotech stock news - UV Flu Technologies, Inc. (OTC.BB: UVFT), a developer, manufacturer and distributor of bio technology products is pleased to announce that the Company has recently completed taping a segment of the "Designing Spaces" TV Show featuring its flagship ViraTech UV-400 air purification system.
The segment will be put on air for national broadcast in late November and again in early December. The show will be aired on the Women's Entertainment channel with specific focus on holiday season health issues and is expected to reach up to 75 million households. Exact dates and times will be made available on the Company website shortly.
The theme of the segment is about staying healthy indoors over the holidays, and the UV-400 offers thought-provoking interest for health conscious consumers. The show provides insights into the UV-400's listing as a Medical Device as a result of rigorous laboratory tests which have conclusively proven that the product kills 99% of airborne bacteria in its patented UV chamber. The UV-400 is designed to easily circulate and filter the air within the average home or work environment multiple times per hour, and this will be demonstrated with real life situations and applications during the television presentation.
Given the amount of time people spend indoors during the Holidays, the show notes that not all health issues come as a result of exposure to bacteria. Many volatile compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. Poor indoor air quality can lead to increases in allergic reactions and other forms of respiratory problems. The alleviation of these problems will be examined and just how the UV-400 purifies the air of these irritants will be shown.
"We hope to educate people to the many dangers associated with poor indoor air quality, and also that our UV-400 is a very cost-effective way to protect themselves. We believe this show is a tremendous platform to reach one of our key markets: concerned parents who value the health of their families," stated John J. Lennon President of UV Flu Technologies.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
"Designing Spaces" TV Broadcast Features Solution for Indoor Air Quality during Holiday Flu and Cold Season
CENTERVILLE, MA - October 21, 2010 (Investorideas.com newswire, www.biotechindusgtrystocks.com ) Biotech stock news - UV Flu Technologies, Inc. (OTC.BB: UVFT), a developer, manufacturer and distributor of bio technology products is pleased to announce that the Company has recently completed taping a segment of the "Designing Spaces" TV Show featuring its flagship ViraTech UV-400 air purification system.
The segment will be put on air for national broadcast in late November and again in early December. The show will be aired on the Women's Entertainment channel with specific focus on holiday season health issues and is expected to reach up to 75 million households. Exact dates and times will be made available on the Company website shortly.
The theme of the segment is about staying healthy indoors over the holidays, and the UV-400 offers thought-provoking interest for health conscious consumers. The show provides insights into the UV-400's listing as a Medical Device as a result of rigorous laboratory tests which have conclusively proven that the product kills 99% of airborne bacteria in its patented UV chamber. The UV-400 is designed to easily circulate and filter the air within the average home or work environment multiple times per hour, and this will be demonstrated with real life situations and applications during the television presentation.
Given the amount of time people spend indoors during the Holidays, the show notes that not all health issues come as a result of exposure to bacteria. Many volatile compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. Poor indoor air quality can lead to increases in allergic reactions and other forms of respiratory problems. The alleviation of these problems will be examined and just how the UV-400 purifies the air of these irritants will be shown.
"We hope to educate people to the many dangers associated with poor indoor air quality, and also that our UV-400 is a very cost-effective way to protect themselves. We believe this show is a tremendous platform to reach one of our key markets: concerned parents who value the health of their families," stated John J. Lennon President of UV Flu Technologies.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Subscribe to:
Posts (Atom)